Franz-Werner Haas, CureVac CEO (Thomas Kienzle/AFP via Getty Images)

Cure­Vac puts lead on­col­o­gy can­di­date on back burn­er and will on­ly move it for­ward in com­bi­na­tion ther­a­pies

Cure­Vac is putting its lead can­cer ther­a­py on ice — for now.

The trans-at­lantic phar­ma with of­fices in Boston, MA and Ger­many put word of the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.